These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
211 related items for PubMed ID: 19594756
1. Molecular mechanisms for the persistent bronchodilatory effect of the beta 2-adrenoceptor agonist salmeterol. Szczuka A, Wennerberg M, Packeu A, Vauquelin G. Br J Pharmacol; 2009 Sep; 158(1):183-94. PubMed ID: 19594756 [Abstract] [Full Text] [Related]
2. Extent of salmeterol-mediated reassertion of relaxation in guinea-pig trachea pretreated with aliphatic side chain structural analogues. Bergendal A, Lindén A, Skoogh BE, Gerspacher M, Anderson GP, Löfdahl CG. Br J Pharmacol; 1996 Mar; 117(6):1009-15. PubMed ID: 8882590 [Abstract] [Full Text] [Related]
3. The reassertion profiles of long acting β2-adrenoceptor agonists in the guinea pig isolated trachea and human recombinant β2-adrenoceptor. Patel S, Summerhill S, Stanley M, Perros-Huguet C, Trevethick MA. Pulm Pharmacol Ther; 2011 Apr; 24(2):247-55. PubMed ID: 21134482 [Abstract] [Full Text] [Related]
4. Why are long-acting beta-adrenoceptor agonists long-acting? Anderson GP, Lindén A, Rabe KF. Eur Respir J; 1994 Mar; 7(3):569-78. PubMed ID: 7912202 [Abstract] [Full Text] [Related]
5. Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor. Green SA, Spasoff AP, Coleman RA, Johnson M, Liggett SB. J Biol Chem; 1996 Sep 27; 271(39):24029-35. PubMed ID: 8798639 [Abstract] [Full Text] [Related]
6. An insilico approach to high altitude pulmonary edema - Molecular modeling of human beta2 adrenergic receptor and its interaction with Salmeterol & Nifedipine. Chandramoorthi GD, Piramanayagam S, Marimuthu P. J Mol Model; 2008 Sep 27; 14(9):849-56. PubMed ID: 18512086 [Abstract] [Full Text] [Related]
7. The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s). Green SA, Rathz DA, Schuster AJ, Liggett SB. Eur J Pharmacol; 2001 Jun 15; 421(3):141-7. PubMed ID: 11516429 [Abstract] [Full Text] [Related]
13. Clinical pharmacokinetics of salmeterol. Cazzola M, Testi R, Matera MG. Clin Pharmacokinet; 2002 Jun 15; 41(1):19-30. PubMed ID: 11825095 [Abstract] [Full Text] [Related]
14. Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists. Lindén A, Rabe KF, Löfdahl CG. Lung; 1996 Jun 15; 174(1):1-22. PubMed ID: 8746998 [Abstract] [Full Text] [Related]
15. On the mechanism of the persistent action of salmeterol: what is the current position? Coleman RA. Br J Pharmacol; 2009 Sep 15; 158(1):180-2. PubMed ID: 19719780 [Abstract] [Full Text] [Related]
16. Comparative trough effects of formoterol and salmeterol on lymphocyte beta2-adrenoceptor--regulation and bronchodilatation. Aziz I, McFarlane LC, Lipworth BJ. Eur J Clin Pharmacol; 1999 Aug 15; 55(6):431-6. PubMed ID: 10492055 [Abstract] [Full Text] [Related]
19. Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol. Grove A, Lipworth BJ. Thorax; 1996 Jan 15; 51(1):54-8. PubMed ID: 8658370 [Abstract] [Full Text] [Related]